Upload
PPT-Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

PPT-Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,

Author : hadly | Published Date : 2023-12-30

Huang SS Labus BJ Samuel MC Wan DT Reingold AL Antibiotic Resistance Patterns of Bacterial Isolates from Blood in San Francisco County California 19961999 Emerg

resistance isolates blood antibiotic

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Figure 4 Figure 4. Yearly perce..." is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,: Transcript

Download Document

Here is the link to download the presentation.
"Figure 4 Figure 4. Yearly percent resistance to ciprofloxacin, ceftazidime, imipenem,"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.

Related Documents

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations

Figure Figure. Kinetics of viremia, CD4+ T-cell count, and drug resistance mutations
Figure 4 Figure 4. a. Hardy-Weinberg equilibrium analysis of the increase in

Figure 4 Figure 4. a. Hardy-Weinberg equilibrium analysis of the increase in
Figure 1 Figure 1. Yearly opportunistic infection rates per 1,000 person-years,

Figure 1 Figure 1. Yearly opportunistic infection rates per 1,000 person-years,
Figure 1 Figure 1. Genetic organization of the antibiotic resistance gene cluster

Figure 1 Figure 1. Genetic organization of the antibiotic resistance gene cluster
Figure 2 Figure 2. Seroconversion in sentinel specific-pathogen-free white leghorns

Figure 2 Figure 2. Seroconversion in sentinel specific-pathogen-free white leghorns
In Vitro Selection of Enterobacter cloacae

In Vitro Selection of Enterobacter cloacae
Figure 3 Figure 3. The yearly incidence of deaths for an incubation period of

Figure 3 Figure 3. The yearly incidence of deaths for an incubation period of
Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative

Figure 3 Figure 3. Resistance rates (%) to selected antimicrobial agents in gram-negative
Figure 2 Figure 2. Proportion of penicillin-nonsusceptible Streptococcus pneumoniae

Figure 2 Figure 2. Proportion of penicillin-nonsusceptible Streptococcus pneumoniae
Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient

Figure 5 Figure 5. 5a simulates combined drug treatment data reported for a patient
Figure 1 Figure 1. Phylogenetic tree of hemagglutinin (HA) segments from 36 avian

Figure 1 Figure 1. Phylogenetic tree of hemagglutinin (HA) segments from 36 avian
Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug

Figure 2 Figure 2. Determination of prevalence of tuberculosis (TB) and drug
Figure 2 Figure 2. Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL)

Figure 2 Figure 2. Effect of addition of clavulanic acid (10 μL of 1,000 μg/mL)